|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Galanty Y, Belotserkovskaya R, Coates J,
Polo S, Miller KM and Jackson SP: Mammalian SUMO E3-ligases PIAS1
and PIAS4 promote responses to DNA double-strand breaks. Nature.
462:935–939. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferguson DO, Sekiguchi JM, Chang S, Frank
KM, Gao Y, DePinho RA and Alt FW: The nonhomologous end-joining
pathway of DNA repair is required for genomic stability and the
suppression of translocations. Proc Natl Acad Sci USA.
97:6630–6633. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vanasse GJ, Halbrook J, Thomas S, Burgess
A, Hoekstra MF, Disteche CM and Willerford DM: Genetic pathsway to
recurrent chromosome translocations in murine lymphoma involves
V(D)J recombinase. J Clin Invest. 103:1669–1675. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao N, Keane MJ, Ong T and Wallace WE:
Effects of simulated pulmonary surfactant on the cytotoxicity and
DNA-damaging activity of respirable quartz and kaolin. J Toxicol
Environ Health A. 60:153–167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nussenzweig A, Chen C, da Costa Soares V,
Sanchez M, Sokol K, Nussenzweig MC and Li GC: Requirement for Ku80
in growth and immunoglobulin V(D)J recombination. Nature.
382:551–555. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhu C, Bogue MA and Roth DB: Thymocyte
differentiation in gamma-irradiated severe-combined immunodeficient
mice: Characterization of intermediates and products of V(D)J
recombination at the T cell receptor alpha locus. Eur J Immunol.
26:2859–2865. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gu Y, Jin S, Gao Y, Weaver DT and Alt FW:
Ku70-deficient embryonic stem cells have increased ionizing
radiosensitivity, defective DNA end-binding activity, and inability
to support V(D)J recombination. Proc Natl Acad Sci USA.
94:8076–8081. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ouyang H, Nussenzweig A, Kurimasa A,
Soares VC, Li X, Cordon-Cardo C, Li W, Cheong N, Nussenzweig M,
Iliakis G, et al: Ku70 is required for DNA repair but not for T
cell antigen receptor gene recombination in vivo. J Exp Med.
186:921–929. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garcia AM, Salomon RN, Witsell A,
Liepkalns J, Calder RB, Lee M, Lundell M, Vijg J and McVey M: Loss
of the bloom syndrome helicase increases DNA ligase 4-independent
genome rearrangements and tumorigenesis in aging Drosophila. Genome
Biol. 12:R1212011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kapusta A, Matsuda A, Marmignon A, Ku M,
Silve A, Meyer E, Forney JD, Malinsky S and Bétermier M: Highly
precise and developmentally programmed genome assembly in
Paramecium requires ligase IV-dependent end joining. PLoS Genet.
7:e10020492011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chistiakov DA, Voronova NV and Chistiakov
PA: Genetic variations in DNA repair genes, radiosensitivity to
cancer and susceptibility to acute tissue reactions in
radiotherapy-treated cancer patients. Acta Oncol. 47:809–824. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roddam PL, Rollinson S, O'Driscoll M,
Jeggo PA, Jack A and Morgan GJ: Genetic variants of NHEJ DNA ligase
IV can affect the risk of developing multiple myeloma, a tumour
characterised by aberrant class switch recombination. J Med Genet.
39:900–905. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu Y, Shete S, Etzel CJ, Scheurer M,
Alexiou G, Armstrong G, Tsavachidis S, Liang FW, Gilbert M, Aldape
K, et al: Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes
involved in the double-strand break repair pathway predict
glioblastoma survival. J Clin Oncol. 28:2467–2474. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kuschel B, Auranen A, McBride S, Novik KL,
Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BA, Pharoah PD,
et al: Variants in DNA double-strand break repair genes and breast
cancer susceptibility. Hum Mol Genet. 11:1399–1407. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sakiyama T, Kohno T, Mimaki S, Ohta T,
Yanagitani N, Sobue T, Kunitoh H, Saito R, Shimizu K, Hirama C, et
al: Association of amino acid substitution polymorphisms in DNA
repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J
Cancer. 114:730–737. 2005. View Article : Google Scholar
|
|
17
|
Li R, Li Y, Fang X, Yang H and Wang J,
Kristiansen K and Wang J: SNP detection for massively parallel
whole-genome resequencing. Genome Res. 19:1124–1132. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pugh TJ, Keyes M, Barclay L, Delaney A,
Krzywinski M, Thomas D, Novik K, Yang C, Agranovich A, McKenzie M,
et al: Sequence variant discovery in DNA repair genes from
radio-sensitive and radiotolerant prostate brachytherapy patients.
Clin Cancer Res. 15:5008–5016. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Damaraju S, Murray D, Dufour J, Carandang
D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, et
al: Association of DNA repair and steroid metabolism gene
polymorphisms with clinical late toxicity in patients treated with
conformal radiotherapy for prostate cancer. Clin Cancer Res.
12:2545–2554. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weischenfeldt J, Simon R, Feuerbach L,
Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H,
Rausch T, et al: Integrative genomic analyses reveal an
androgen-driven somatic alteration landscape in early-onset
prostate cancer. Cancer Cell. 23:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Barbieri CE, Baca SC, Lawrence MS,
Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van
Allen E, Stransky N, et al: Exome sequencing identifies recurrent
SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet.
44:685–689. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Erbersdobler A, Fritz H, Schnöger S,
Graefen M, Hammerer P, Huland H and Henke RP: Tumour grade,
proliferation, apoptosis, microvessel density, p53, and bcl-2 in
prostate cancers: Differences between tumours located in the
transition zone and in the peripheral zone. Eur Urol. 41:40–46.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mirlacher M and Simon R: Recipient block
TMA technique. Methods Mol Biol. 664:37–44. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Minner S, Enodien M, Sirma H, Luebke AM,
Krohn A, Mayer PS, Simon R, Tennstedt P, Müller J, Scholz L, et al:
ERG status is unrelated to PSA recurrence in radically operated
prostate cancer in the absence of antihormonal therapy. Clin Cancer
Res. 17:5878–5888. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Burkhardt L, Fuchs S, Krohn A, Masser S,
Mader M, Kluth M, Bachmann F, Huland H, Steuber T, Graefen M, et
al: CHD1 is a 5q21 tumor suppressor required for ERG rearrangement
in prostate cancer. Cancer Res. 73:2795–2805. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kluth M, Hesse J, Heinl A, Krohn A,
Steurer S, Sirma H, Simon R, Mayer PS, Schumacher U, Grupp K, et
al: Genomic deletion of MAP3K7 at 6q12-22 is associated with early
PSA recurrence in prostate cancer and absence of TMPRSS2:ERG
fusions. Mod Pathol. 26:975–983. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Krohn A, Diedler T, Burkhardt L, Mayer PS,
De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J,
Gerhäuser C, et al: Genomic deletion of PTEN is associated with
tumor progression and early PSA recurrence in ERG fusion-positive
and fusion-negative prostate cancer. Am J Pathol. 181:401–412.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krohn A, Seidel A, Burkhardt L, Bachmann
F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, et
al: Recurrent deletion of 3p13 targets multiple tumour suppressor
genes and defines a distinct subgroup of aggressive ERG
fusion-positive prostate cancers. J Pathol. 231:130–141. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Berger MF, Lawrence MS, Demichelis F,
Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger
D, Sougnez C, et al: The genomic complexity of primary human
prostate cancer. Nature. s470:214–220. 2011. View Article : Google Scholar
|
|
30
|
Lapointe J, Li C, Giacomini CP, Salari K,
Huang S, Wang P, Ferrari M, Hernandez-Boussard T, Brooks JD and
Pollack JR: Genomic profiling reveals alternative genetic pathways
of prostate tumorigenesis. Cancer Res. 67:8504–8510. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Taylor BS, Schultz N, Hieronymus H,
Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva
B, et al: Integrative genomic profiling of human prostate cancer.
Cancer Cell. 18:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Barnes DE, Stamp G, Rosewell I, Denzel A
and Lindahl T: Targeted disruption of the gene encoding DNA ligase
IV leads to lethality in embryonic mice. Curr Biol. 8:1395–1398.
1998. View Article : Google Scholar
|
|
33
|
Frank KM, Sekiguchi JM, Seidl KJ, Swat W,
Rathbun GA, Cheng HL, Davidson L, Kangaloo L and Alt FW: Late
embryonic lethality and impaired V(D)J recombination in mice
lacking DNA ligase IV. Nature. 396:173–177. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gao Y, Sun Y, Frank KM, Dikkes P, Fujiwara
Y, Seidl KJ, Sekiguchi JM, Rathbun GA, Swat W, Wang J, et al: A
critical role for DNA end-joining proteins in both lymphogenesis
and neurogenesis. Cell. 95:891–902. 1998. View Article : Google Scholar
|
|
35
|
Gatz SA, Ju L, Gruber R, Hoffmann E, Carr
AM, Wang ZQ, Liu C and Jeggo PA: Requirement for DNA ligase IV
during embryonic neuronal development. J Neurosci. 31:10088–10100.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jeggo PA: Identification of genes involved
in repair of DNA double-strand breaks in mammalian cells. Radiat
Res. 150(Suppl 5): S80–S91. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tomlins SA, Rhodes DR, Perner S,
Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J,
Kuefer R, et al: Recurrent fusion of TMPRSS2 and ETS transcription
factor genes in prostate cancer. Science. 310:644–648. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Haffner MC, Aryee MJ, Toubaji A, Esopi DM,
Albadine R, Gurel B, Isaacs WB, Bova GS, Liu W, Xu J, et al:
Androgen-induced TOP2B-mediated double-strand breaks and prostate
cancer gene rearrangements. Nat Genet. 42:668–675. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Deweese JE and Osheroff N: Coordinating
the two protomer active sites of human topoisomerase IIalpha: Nicks
as topoisomerase II poisons. Biochemistry. 48:1439–1441. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Haffner MC, De Marzo AM, Meeker AK, Nelson
WG and Yegnasubramanian S: Transcription-induced DNA double strand
breaks: Both oncogenic force and potential therapeutic target? Clin
Cancer Res. 17:3858–3864. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tomkinson AE and Mackey ZB: Structure and
function of mammalian DNA ligases. Mutat Res. 407:1–9. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Huang FC, Huang KF, Chen RH, Wu JE, Chen
TC, Chen CL, Lee CC, Chen JY, Lin JJ and Huang HS: Synthesis,
telomerase evaluation and anti-proliferative studies on various
series of diaminoanthraquinone-linked aminoacyl residue
derivatives. Arch Pharm (Weinheim). 345:101–111. 2012. View Article : Google Scholar
|
|
43
|
Liu W, Lindberg J, Sui G, Luo J, Egevad L,
Li T, Xie C, Wan M, Kim ST, Wang Z, et al: Identification of novel
CHD1-associated collaborative alterations of genomic structure and
functional assessment of CHD1 in prostate cancer. Oncogene.
31:3939–3948. 2012. View Article : Google Scholar
|
|
44
|
Varga T and Aplan PD: Chromosomal
aberrations induced by double strand DNA breaks. DNA Repair (Amst).
4:1038–1046. 2005. View Article : Google Scholar
|
|
45
|
Schlade-Bartusiak K, Tucker T, Safavi H,
Livingston J, van Allen MI, Eydoux P and Armstrong L: Independent
post-zygotic breaks of a dicentric chromosome result in mosaicism
for an inverted duplication deletion 9p and terminal deletion 9p.
Eur J Med Genet. 56:229–235. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Carter SL, Eklund AC, Kohane IS, Harris LN
and Szallasi Z: A signature of chromosomal instability inferred
from gene expression profiles predicts clinical outcome in multiple
human cancers. Nat Genet. 38:1043–1048. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Walther A, Houlston R and Tomlinson I:
Association between chromosomal instability and prognosis in
colorectal cancer: A meta-analysis. Gut. 57:941–950. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Schlomm T, Iwers L, Kirstein P, Jessen B,
Köllermann J, Minner S, Passow-Drolet A, Mirlacher M,
Milde-Langosch K, Graefen M, et al: Clinical significance of p53
alterations in surgically treated prostate cancers. Mod Pathol.
21:1371–1378. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bubendorf L, Sauter G, Moch H, Schmid HP,
Gasser TC, Jordan P and Mihatsch MJ: Ki67 labelling index: An
independent predictor of progression in prostate cancer treated by
radical prostatectomy. J Pathol. 178:437–441. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
El Gammal AT, Brüchmann M, Zustin J,
Isbarn H, Hellwinkel OJ, Köllermann J, Sauter G, Simon R, Wilczak
W, Schwarz J, et al: Chromosome 8p deletions and 8q gains are
associated with tumor progression and poor prognosis in prostate
cancer. Clin Cancer Res. 16:56–64. 2010. View Article : Google Scholar
|
|
51
|
Grupp K, Kohl S, Sirma H, Simon R, Steurer
S, Becker A, Adam M, Izbicki J, Sauter G, Minner S, et al:
Cysteine-rich secretory protein 3 overexpression is linked to a
subset of PTEN-deleted ERG fusion-positive prostate cancers with
early biochemical recurrence. Mod Pathol. 26:733–742. 2013.
View Article : Google Scholar
|
